Vega enters the galaxy with bleeding disorder antibody set for 2023 trial

Biotech incubator Star Therapeutics has launched another galaxy-themed drug developer, which next year will test a new antibody in a bleeding disorder currently treated by Takeda’s Vonvendi.

Star lined up a who’s who of biotech venture capital firms to line Vega Therapeutics’ coffers with $40 million. The funds will bankroll a Phase I study early next year as the biotech recently got the go-ahead from Austrian authorities, CEO Adam Rosenthal told Endpoints News in a preview of the unveiling. The biotech will test whether a monoclonal antibody can treat one of the most common forms of inherited bleeding disorders: von Willebrand disease, or VWD.